人工智能
，Artificial Intelligence，已成为一道亮丽的风景线而吸引人们的注意力。比尔·盖茨先生在谈到当下能对世界产生巨大影响的机会时推荐三个领域——人工智能、能源以及生物科学。因为人工智能可以使人们生活更有效率和具有创造力。我们药时代一直关注人工智能在医药研发领域的应用，分享过多篇文章。
今天，我们向朋友们推荐的是
人工智能助力临床试验受试者招募
，希望帮助临床试验
更加精准，成功的几率更高
。TD2和Deep 6 AI 这两家公司宣布建立合作伙伴关系，以加速肿瘤临床试验受试者招募。欢迎朋友们阅读新闻稿，了解详情！
TD2 and Deep 6 AI Announce Partnership to Accelerate Oncology Clinical Trial Recruitment
Artificial intelligence used to identify potential clinical trial participants in minutes
SCOTTSDALE, Ariz. and PASADENA, Calif. (May 31, 2017)
–
Translational Drug Development (TD2
) and
Deep 6 AI
announced today a formal agreement to work together in the fields of oncology and fibrosis to rapidly match eligible patients with appropriate clinical trials.
The partnership grants TD2—an oncology development organization—access to cutting-edge artificial intelligence provided by Deep 6 AI, a company dedicated to finding patients for clinical trials. With the ability to analyze all structured and unstructured clinical data, including physician notes and pathology and genomic reports, Deep 6 AI’s system expedites the process of matching patients with new drug trials—finding suitable participants in minutes rather than the months it takes to manually review patient records.
“Partnering with Deep 6 AI allows TD2 to provide patients with rapid access to the newest, most advanced medicines. Our sponsor companies benefit from more timely study enrollment and patient identification that precisely matches study protocols, increasing the opportunity to demonstrate clinical activity for new medicines earlier in development,” said
Stephen Gately
, CEO of TD2.
This new approach allows TD2 to continuously monitor the number of eligible patients with specific cancers who are available to participate in a clinical study; identify patient populations that are rare in incidence or genomic context to define trial and regulatory opportunities; and develop dynamic protocols with inclusion/exclusion criteria based on real-time patient data.
“The partnership will advance our shared mission of getting cutting-edge treatments to patients more quickly,” said
Wout Brusselaers
, CEO of Deep 6 AI. “We’re thrilled to offer TD2 the ability to mine real-time patient data to guide trial feasibility and design, site selection and patient enrollment. Together we will significantly accelerate medical research.”
Over the coming months, TD2 and Deep 6 AI will establish a network of the top Phase 1 and 2 sites in oncology clinical trials to expand site and industry access to patient electronic data.
ABOUT TD2
Translational Drug Development (TD2)
is an oncology development organization that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit
www.td2inc.com
. TD2 is a portfolio company of
ORIX USA Corporation
.
